Back

SLC13A2-transported citrate is a metabolic signal for PKM2 acetylation and degradation to suppress tumor growth

Xiong, J.; Hao, H.; Qin, M.; Shi, L.; Chen, H.; Liu, C.; Tang, Z.; An, D.; Yu, W.; He, D.; Shao, C.; Yuan, S.; Yu, H.

2024-12-04 cancer biology
10.1101/2024.05.04.591017 bioRxiv
Show abstract

Background and aimsMetabolic reprogramming represents as a pivotal hallmark for cancer, but TCA cycle in tumorigenesis and progression has long been neglected. Solute carrier (SLC) transporters mediate the transport of TCA cycle intermediates across membrane, but their functions in cancer pathogenesis remains unclear. Approaches & ResultsUsing integrated analysis of solute carrier (SLC) transporters for TCA cycle intermediates, we found that SLC13A2 was consistently downregulated in hepatocellular carcinoma (HCC) cells and liver tissues from human patients and heterogeneous mouse models. Adeno-associated virus (AAV)-transduced liver-specific knockout or overexpression of SLC13A2 promoted or ameliorated HCC progression in the primary mouse model, demonstrating that SLC13A2 served as a protective factor during HCC pathogenesis. SLC13A2 inhibited HCC cell proliferation by decreasing mitochondrial function via suppressed oxygen consumption and ATP production. Combined with metabolic flux analysis, we found that SLC13A2 imported citrate, which secreted acetyl-CoA as a precursor for the acetylation of pyruvate kinase muscle isozyme M2 (PKM2), which led to its protein degradation. Decreased activity of pyruvate kinase depleted pyruvate for the TCA cycle, thus inhibiting amino acid synthesis and nucleotide metabolism. Additionally, a decrease in nuclear PKM2 protein transduced to reprogrammed gene transcription for cell proliferation and metabolism which is required for tumor growth. ConclusionsThis study revealed that citrate transported by SLC13A2 acts as a signal to disrupt metabolic homeostasis for tumor growth and suggests potential drug targets for HCC therapy. graphic abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=165 SRC="FIGDIR/small/591017v2_ufig1.gif" ALT="Figure 1"> View larger version (64K): org.highwire.dtl.DTLVardef@80c95eorg.highwire.dtl.DTLVardef@124750corg.highwire.dtl.DTLVardef@809ab4org.highwire.dtl.DTLVardef@12cbe74_HPS_FORMAT_FIGEXP M_FIG C_FIG

Matching journals

The top 16 journals account for 50% of the predicted probability mass.

1
Journal of Translational Medicine
46 papers in training set
Top 0.1%
8.7%
2
Frontiers in Oncology
95 papers in training set
Top 0.3%
7.4%
3
Cancers
200 papers in training set
Top 1%
4.1%
4
Hepatology
18 papers in training set
Top 0.1%
3.7%
5
PLOS ONE
4510 papers in training set
Top 37%
3.7%
6
British Journal of Cancer
42 papers in training set
Top 0.5%
2.7%
7
BMC Cancer
52 papers in training set
Top 0.8%
2.7%
8
BMC Medicine
163 papers in training set
Top 2%
2.4%
9
PeerJ
261 papers in training set
Top 4%
2.4%
10
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 3%
2.1%
11
International Journal of Molecular Sciences
453 papers in training set
Top 5%
2.1%
12
Neoplasia
22 papers in training set
Top 0.1%
1.9%
13
Journal of Clinical Medicine
91 papers in training set
Top 3%
1.9%
14
Metabolomics
11 papers in training set
Top 0.1%
1.7%
15
Frontiers in Pharmacology
100 papers in training set
Top 2%
1.7%
16
Frontiers in Molecular Biosciences
100 papers in training set
Top 1%
1.7%
50% of probability mass above
17
Scientific Reports
3102 papers in training set
Top 61%
1.5%
18
PLOS Computational Biology
1633 papers in training set
Top 19%
1.3%
19
Translational Oncology
18 papers in training set
Top 0.2%
1.3%
20
Biochemistry and Biophysics Reports
28 papers in training set
Top 0.8%
1.3%
21
Molecules
37 papers in training set
Top 1%
1.1%
22
The FASEB Journal
175 papers in training set
Top 2%
1.1%
23
Hepatology Communications
21 papers in training set
Top 0.3%
1.1%
24
eBioMedicine
130 papers in training set
Top 3%
1.0%
25
Journal of Cellular Biochemistry
10 papers in training set
Top 0.1%
1.0%
26
Computers in Biology and Medicine
120 papers in training set
Top 4%
0.9%
27
Frontiers in Genetics
197 papers in training set
Top 8%
0.9%
28
Journal of Hepatology
18 papers in training set
Top 0.3%
0.9%
29
Biomolecules
95 papers in training set
Top 1%
0.9%
30
Metabolic Engineering
68 papers in training set
Top 0.6%
0.8%